Systemic Antibiotics Market

Systemic Antibiotics Market - Introduction Antibiotics are indispensable medicines for the treatment of life-threatening disorders and infections. Systemic antibiotics are antibiotics used in the treatment of bacterial infections, administered orally or intravenously i.e., directly into the blood stream of patients. Systemic antibiotics work throughout the body and help in resolution of infections.

Systemic antibiotics are used to treat urinary tract infections, skin infections, dental diseases, and other bacterial infections. Amoxicillin, cephalosporin, macrolide, tetracycline, and metronidazole are major systemic antibiotics used for the treatment of dental disorders including periodontal and endodontic diseases. Moreover, tetracycline class of antibiotics are considered first-line therapy for severe acne which work by inhibiting the protein synthesis by binding the 30S subunit of the bacterial ribosome. Furthermore, macrolides such as azithromycin and erythromycin are used for the treatment of acne.

ReportOverview: https://www.transparencymarketresearch.com/systemic-antibioticsmarket.html Systemic Antibiotics Market – Competitive Landscape 

In June 2019, Merck & Co. Inc. received U.S. Food and Drug Administration (FDA) approval for ZERBAXA for the treatment of adults with hospital-acquired bacterial infections.



In June 2017, Melinta Therapeutics received U.S. Food and Drug Administration (FDA) approval for its drug Baxelda. The new drug is available as an injectable and oral tablet form for the treatment of patients with acute bacterial skin or skin structure infections (ABSSSI).

GlaxoSmithKline Founded in 2000, GlaxoSmithKline is a leading firm involved in developing and manufacturing of innovative consumer healthcare products, vaccines, and pharmaceutical medicines. The company focuses on research activities for the development of novel systemic antibiotics for the treatment of gram-negative bacterial infections.

Merck & Co., Inc. Incorporated in 1970, Merck & Co., Inc. is based in Kenilworth, New Jersey. Merck & Co., Inc. is a global health care provider primarily engaged in delivering innovative health solutions through vaccines, prescription medicines, animal health products, and biological therapies. The company invests in research and development (R&D) of

infectious diseases to address unmet medical needs of patients. The firm operates in more than 140 countries to deliver novel health solutions.

Melinta Therapeutics, Inc. Established in 2000, Melinta Therapeutics, Inc. is a leading pharmaceutical company engaged in manufacture and commercialization of differentiated anti-infectives for hospital and other healthcare settings. The company focuses on partnership with leading pharmaceutical companies for distribution of Baxdela in regions based outside the U.S. For instance, the firm has partnered with Eurofarma Laboratories S.A. for distribution of its drug in Central and South America and with Menarini for distribution in Europe and Asia-Pacific countries excluding Japan.

Other prominent players operating in the global systemic antibiotics market are Pfizer, Inc., Bayer Healthcare AG, Cubist Pharmaceuticals, AstraZeneca, MerLion Pharmaceuticals Pte Ltd., and Johnson & Johnson. These players have adopted organic and in-organic growth strategies to expand product portfolio and strengthen market foothold. Moreover, innovation of new antibiotics by leading industry players targeting gram-negative bacteria is expected to effectively combat antibiotic resistance and drive the global market in the next few years.

Systemic Antibiotics Market - Dynamics Rise in Prevalence of Chronic Diseases Globally Drives Market Increase in incidence of infectious and chronic diseases and rise in prevalence of dental disorders are the major factors driving the global systemic antibiotics market.

Periodontal diseases and tooth loss and decay are highly common dental disorders across the globe. For instance, it is estimated that periodontal disease is highly prevalent in the geriatric population and affects 20% to 50% of the population globally.

Moreover, diabetic mellitus leading to diabetic foot infections, urinary tract infections, and other contagious diseases is rising across the globe. This is projected to fuel the demand for systemic antibiotics in the next few years. Rise in skin infections and other chronic wounds is likely to boost demand for systemic antibiotics during the forecast period.

Favorable Government Initiatives and Increase in Investment in R&D Propels Market Increase in investment in research and development for new drug development is anticipated to augment the global systemic antibiotics market during the forecast period. For instance, the U.S. invested US$ 260 Mn and US$ 410 Mn in antibiotic R&D activities in 2015 and 2016, respectively.

Moreover, launch and implementation of various government initiatives such as antibiotic stewardship by CDC to promote the appropriate use of antibiotics and reduce antimicrobial resistance is expected to augment the global systemic antibiotics market during the forecast period.

Adverse Reactions and Antibiotic Resistance to Impede the Systemic Antibiotics Market Emergence of antibiotic resistance by various species of bacteria and adverse reactions including allergic reactions, hypersensitivity reactions, anaphylaxis, and rashes associated with intake of systemic antibiotics are expected to restrain the global market in the near future. For instance, tinnitus, dizziness, pigment deposition of skin, pharyngitis, gastrointestinal disturbances, C. difficile infection, photosensitivity caused due to tetracycline, and macrolides during acne treatment are anticipated to hamper the growth of the global systemic antibiotics market in the next few years.

Request

Brochure:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=67568

North America to Dominate the Systemic Antibiotics Market Increase in incidence of diabetes mellitus leading to diabetic foot infections in the U.S. is a major factor contributing to the dominant share of North America during the forecast period. Based on National Diabetes Statistics Report 2017 by CDC, 30.3 million people in the U.S. have diabetes. According to the American Diabetes Association (ADA), annual incidence of foot ulcers in diabetes patients ranges from 2% to 8% in the U.S. Furthermore, strong pipeline of antibiotics is anticipated to drive the market in the U.S. in the next few years. According to the World Health Organization (WHO), there were around 39 systemic antibiotics in varying clinical development phases in the U.S. in 2015. All these factors are anticipated to drive the market in North America.

About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our realtime data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination

of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/